Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii.

Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G.

Antimicrob Agents Chemother. 2014;58(1):518-26. doi: 10.1128/AAC.01597-13. Epub 2013 Nov 4.

2.

Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.

López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y, Fernández-Reyes M, Rivas L, Pachón J.

J Infect Dis. 2011 Feb 15;203(4):545-8. doi: 10.1093/infdis/jiq086. Epub 2011 Jan 7.

3.

Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii.

Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):222-6. doi: 10.1016/j.diagmicrobio.2015.03.013. Epub 2015 Mar 25.

PMID:
25858028
4.

Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.

Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N.

Antimicrob Agents Chemother. 2011 Jul;55(7):3370-9. doi: 10.1128/AAC.00079-11. Epub 2011 May 16.

5.

Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance.

Wand ME, Bock LJ, Bonney LC, Sutton JM.

J Antimicrob Chemother. 2015 Aug;70(8):2209-16. doi: 10.1093/jac/dkv097. Epub 2015 Apr 22.

PMID:
25904728
6.

Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.

Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD.

Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7. doi: 10.1128/AAC.00834-10. Epub 2010 Sep 20.

7.

Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii.

Park YK, Choi JY, Shin D, Ko KS.

Int J Antimicrob Agents. 2011 Jun;37(6):525-30. doi: 10.1016/j.ijantimicag.2011.02.008. Epub 2011 Apr 14.

PMID:
21497062
8.

Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.

López-Rojas R, McConnell MJ, Jiménez-Mejías ME, Domínguez-Herrera J, Fernández-Cuenca F, Pachón J.

Antimicrob Agents Chemother. 2013 Sep;57(9):4587-9. doi: 10.1128/AAC.00543-13. Epub 2013 Jul 8.

9.

Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment.

Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J.

J Antimicrob Chemother. 2011 Jan;66(1):126-33. doi: 10.1093/jac/dkq422. Epub 2010 Nov 16.

10.

Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia.

Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain JM, Raoult D, Brunel JM, Papazian L, Brégeon F.

Antimicrob Agents Chemother. 2013 Oct;57(10):5120-1. doi: 10.1128/AAC.00700-13. Epub 2013 Jul 8.

11.

Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii.

López-Rojas R, García-Quintanilla M, Labrador-Herrera G, Pachón J, McConnell MJ.

Int J Antimicrob Agents. 2016 Jun;47(6):473-7. doi: 10.1016/j.ijantimicag.2016.03.010. Epub 2016 Apr 22.

PMID:
27179817
12.

Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.

Cai Y, Chai D, Wang R, Liang B, Bai N.

J Antimicrob Chemother. 2012 Jul;67(7):1607-15. doi: 10.1093/jac/dks084. Epub 2012 Mar 22. Review.

PMID:
22441575
13.

Loss of LPS is involved in the virulence and resistance to colistin of colistin-resistant Acinetobacter nosocomialis mutants selected in vitro.

Vila-Farrés X, Ferrer-Navarro M, Callarisa AE, Martí S, Espinal P, Gupta S, Rolain JM, Giralt E, Vila J.

J Antimicrob Chemother. 2015 Nov;70(11):2981-6. doi: 10.1093/jac/dkv244. Epub 2015 Aug 25.

PMID:
26311838
14.

Optimisation of the Caenorhabditis elegans model for studying the pathogenesis of opportunistic Acinetobacter baumannii.

Vallejo JA, Beceiro A, Rumbo-Feal S, Rodríguez-Palero MJ, Russo TA, Bou G.

Int J Antimicrob Agents. 2015 Jul 9. pii: S0924-8579(15)00241-1. doi: 10.1016/j.ijantimicag.2015.05.021. [Epub ahead of print]

PMID:
26213382
15.

Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA.

Antimicrob Agents Chemother. 2009 Sep;53(9):3628-34. doi: 10.1128/AAC.00284-09. Epub 2009 Jun 15.

16.

The Effect of Colistin Resistance-Associated Mutations on the Fitness of Acinetobacter baumannii.

Mu X, Wang N, Li X, Shi K, Zhou Z, Yu Y, Hua X.

Front Microbiol. 2016 Nov 1;7:1715. eCollection 2016.

17.

Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamine.

Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD.

Antimicrob Agents Chemother. 2012 Jan;56(1):59-69. doi: 10.1128/AAC.05191-11. Epub 2011 Oct 24.

18.

Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections.

Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE.

J Infect Dis. 2013 Oct 1;208(7):1142-51. doi: 10.1093/infdis/jit293. Epub 2013 Jun 28.

PMID:
23812239
19.

In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection.

Hornsey M, Wareham DW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3534-7. doi: 10.1128/AAC.00230-11. Epub 2011 Apr 18.

20.

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Dudhani RV, Turnidge JD, Nation RL, Li J.

J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23.

Supplemental Content

Support Center